Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 3 crawled date : 2021 - 06 - 01 save search
Taltz® Showed Consistent, Long-Term Improvement in Key Signs and Symptoms of Axial Spondyloarthritis Through Two Years in Phase 3 Study
Published: 2021-06-01 (Crawled : 23:00) - prnewswire.com
LLY | News | $731.33 0.69% 0.36% 1.7M
|
Health Technology
|
| O: 0.3%
H: 0.96%
C: 0.06%
phase 3
BeiGene Announces First Presentation of the Phase 3 ALPINE Trial Comparing BRUKINSA® (Zanubrutinib) to Ibrutinib in Chronic Lymphocytic Leukemia to Be Featured in Presidential Symposium at EHA2021
Published: 2021-06-01 (Crawled : 15:00) - biospace.com/
BGNE | $130.94 1.1% 1.24% 130K
|
Health Technology
|
| O: 0.42%
H: 2.35%
C: 1.95%
presentation brukinsa leukemia phase 3 trial symposium
Brickell Biotech Announces Publication of Japan Phase 3 Long-Term Safety and Efficacy Study Results for Sofpironium Bromide Gel, 5% (ECCLOCK®) in the Journal of Dermatology
Published: 2021-06-01 (Crawled : 14:00) - globenewswire.com
BBI | $2.12 16.04%
|
Health Technology
|
| O: 0.59%
H: 12.2%
C: 6.1%
results biotech phase 3 iot
Biogen and Bio-Thera Announce Positive Results From Phase 3 Study of BAT1806, a Proposed Biosimilar Referencing Actemra® (Tocilizumab)
Published: 2021-06-01 (Crawled : 12:00) - globenewswire.com
BIIB | $194.11 -0.14% -0.15% 930K
|
Health Technology
|
| O: 1.82%
H: 0.0%
C: -1.91%
positive results positive results phase 3 biosimilar
Alnylam Completes Enrollment in APOLLO-B Phase 3 Study of Patisiran in Transthyretin-Mediated (ATTR) Amyloidosis Patients with Cardiomyopathy
Published: 2021-06-01 (Crawled : 12:00) - biospace.com/
ALNY | $145.79 0.96% 0.94% 400K
|
Health Technology
|
| O: 0.17%
H: 2.05%
C: 1.44%
media phase 3 cardio enroll
Amgen and Kyowa Kirin to Jointly Develop and Commercialize KHK4083, a Phase 3-Ready, Potential First-In-Class Treatment for Atopic Dermatitis
Published: 2021-06-01 (Crawled : 09:00) - biospace.com/
BGNE | $130.94 1.1% 1.24% 130K
|
Health Technology
|
| O: 0.42%
H: 2.35%
C: 1.95%
AMGN | News | $271.91 1.11% 1.12% 1.4M
|
Health Technology
|
| O: 1.79%
H: 0.03%
C: -3.56%
treatment potential dermatitis phase 3 atopic dermatitis
Gainers vs Losers
| 73% | 27% |
Top 10 Gainers
MTTR | News M | $4.8 175.86% 63.6% 71M
|
AGBA | $2.5 100.0% 56.6% 200M
|
Finance
MLEC | $2.47 76.43% 42.62% 78M
|
n/a
NUWE | $0.334 29.96% 40.99% 2.5M
|
Manufacturing
EDBL | News | $6.26 66.49% 40.13% 16M
|
ATGL | $2.86 46.25% 32.8% 180K
|
ONFO | $0.6088 38.68% 27.74% 7.3M
|
n/a
VIVK | $1.43 33.65% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.7M
|
SDIG A | $3.64 35.32% 26.0% 990K
|
Your saved searches
Save your searches and get alerts when important news are released.